Abstract
Diabetes mellitus represents an increasing health problem worldwide. Renal involvement in diabetic patients occurs in a subset of these patients, often playing a key role in morbidity and mortality. Diabetic nephropathy is the major cause of chronic renal disease and end-stage renal disease in the United States, accounting for about half of the patients entering dialysis each year.
Diabetic nephropathy occurs in only approximately one third (20–40 %) of patients with diabetes mellitus, generally 15–20 years after diagnosis. A significant genetic component must be at least part of the explanation as to why only some patients with diabetes mellitus develop nephropathy.
Characteristic lesions can be seen in glomeruli but there are also concomitant vascular alterations and secondary tubular interstitial alterations, all combining to lead to renal failure in many of these patients.
Morphological findings in diabetes mellitus can be pathognomonic or rather nonspecific. The latter most typically happens in early cases but can also occur in situations where diabetic changes are found concomitantly with morphological manifestations of other superimposed disorders, mostly glomerulopathies.
The differential diagnosis of nodular glomerulosclerosis, the classical glomerular lesion seen in well-established diabetic nephropathy, includes a number of other similar glomerulopathies that share similar pathogenetic molecular mechanisms, though their etiology is completely different. Recognition of these entities is imperative to avoid making the wrong assessment and/or delaying diagnosis.
The present chapter addresses the morphological expressions of type 1 and 2 diabetes mellitus in the renal parenchyma with emphasis on structural changes that take place, pathology, differential diagnosis, pathogenesis, and clinical correlations.
It also emphasizes underlying molecular events responsible for the pathological abnormalities to be able to understand why other totally different disorders may share morphological similarities. Future therapeutic interventions will likely take advantage of our more sophisticated understanding of the pathogenesis of diabetic nephropathy. Finally, the chapter attempts to correlate pathological findings with clinical manifestations, progression, and ultimately, prognosis. Other disorders that may exist concomitantly in a given case that may alter the morphological and clinical manifestations will also be discussed to provide a rather comprehensive view of the subject.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol. 1936;12:83–98.7.
Murakami R. Beitrag zur Kenntnis der Veränderung des Nierenkörperchens beim Diabetes mellitus. Trans Jpn Pathol Soc. 1936;26:657–64.
Gellman DD, Pirani CL, Soothill JF, Muehrcke RC, Kark RM. Diabetic nephropathy: a clinical and pathologic study based on renal biopsies. Medicine (Baltimore). 1959;38:321–67.
Dalla Vestra M, Saller A, Mauer M, Fioretto P. Role of mesangial expansion in the pathogenesis of diabetic nephropathy. J Nephrol. 2001;14 Suppl 4:S51–7.
Mogensen CE, Andersen MJ. Increased kidney size and glomerular filtration rate in early juvenile diabetes. Diabetes. 1973;22:706–12.
Drummond K, Mauer M. The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes. 2002;51:1580–7.
Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab. 2000;26 Suppl 4:8–14.
Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest. 1984;74:1143–55.
Ritz E, Zeng XX, Rychlik I. Clinical manifestation and natural history of diabetic nephropathy. Contrib Nephrol. 2011;170:19–27.
Ritz E. Diabetic nephropathy. Saudi J Kidney Dis Transpl. 2006;17:481–90.
Ellis EN, Warady BA, Wood EG, et al. Renal structural-functional relationships in early diabetes mellitus. Pediatr Nephrol. 1997;11:584–91.
Jeansson M, Granqvist AB, Nystrom JS, Haraldsson B. Functional and molecular alterations of the glomerular barrier in long-term diabetes in mice. Diabetologia. 2006;49:2200–9.
Flyvbjerg A. Inhibition and reversibility of renal changes: lessons from diabetic kidney disease. Acta Paediatr Suppl. 2006;95:83–92.
Qian Y, Feldman E, Pennathur S, Kretzler M, Brosius 3rd FC. From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes. 2008;57:1439–45.
Osterby R, Gall MA, Schmitz A, Nielsen FS, Nyberg G, Parving HH. Glomerular structure and function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:1064–70.
Dische FE. Measurement of glomerular basement membrane thickness and its application to the diagnosis of thin-membrane nephropathy. Arch Pathol Lab Med. 1992;116:43–9.
Haas M. Alport syndrome and thin glomerular basement membrane nephropathy: a practical approach to diagnosis. Arch Pathol Lab Med. 2009;133:224–32.
Nasr SH, Markowitz GS, Valeri AM, Yu Z, Chen L, D’Agati VD. Thin basement membrane nephropathy cannot be diagnosed reliably in deparaffinized, formalin-fixed tissue. Nephrol Dial Transplant. 2007;22:1228–32.
Najafian B, Alpers CE, Fogo AB. Pathology of human diabetic nephropathy. Contrib Nephrol. 2011;170:36–47.
Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev. 2008;4:39–45.
Stout LC, Kumar S, Whorton EB. Focal mesangiolysis and the pathogenesis of the Kimmelstiel-Wilson nodule. Hum Pathol. 1993;24:77–89.
Wada T, Shimizu M, Yokoyama H, et al. Nodular lesions and mesangiolysis in diabetic nephropathy. Clin Exp Nephrol. 2013;17:3–9.
Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21:556–63.
Matsusaka T, Xin J, Niwa S, et al. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol. 2005;16:1013–23.
Stout LC, Kumar S, Whorton EB. Insudative lesions—their pathogenesis and association with glomerular obsolescence in diabetes: a dynamic hypothesis based on single views of advancing human diabetic nephropathy. Hum Pathol. 1994;25:1213–27.
Alsaad KO, Herzenberg AM. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol. 2007;60:18–26.
Bader R, Bader H, Grund KE, Mackensen-Haen S, Christ H, Bohle A. Structure and function of the kidney in diabetic glomerulosclerosis. Correlations between morphological and functional parameters. Pathol Res Pract. 1980;167:204–16.
Mauer SM, Sutherland DE, Steffes MW. Relationship of systemic blood pressure to nephropathology in insulin-dependent diabetes mellitus. Kidney Int. 1992;41:736–40.
Fioretto P, Steffes MW, Sutherland DE, Mauer M. Sequential renal biopsies in insulin-dependent diabetic patients: structural factors associated with clinical progression. Kidney Int. 1995;48:1929–35.
Caramori ML, Kim Y, Huang C, et al. Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. Diabetes. 2002;51:506–13.
Perrin NE, Torbjornsdotter TB, Jaremko GA, Berg UB. The course of diabetic glomerulopathy in patients with type I diabetes: a 6-year follow-up with serial biopsies. Kidney Int. 2006;69:699–705.
Caramori ML, Parks A, Mauer M. Renal lesions predict progression of diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol. 2013;24:1175–81.
Teiken JM, Audettey JL, Laturnus DI, Zheng S, Epstein PN, Carlson EC. Podocyte loss in aging OVE26 diabetic mice. Anat Rec (Hoboken). 2008;291:114–21.
Bohle A, Wehrmann M, Bogenschutz O, Batz C, Muller CA, Muller GA. The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract. 1991;187:251–9.
Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol. 2003;14:1358–73.
Pichaiwong W, Hudkins KL, Wietecha T, et al. Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. J Am Soc Nephrol. 2013;24:1088–102.
Berg UB, Torbjornsdotter TB, Jaremko G, Thalme B. Kidney morphological changes in relation to long-term renal function and metabolic control in adolescents with IDDM. Diabetologia. 1998;41:1047–56.
Tamsma JT, van den Born J, Bruijn JA, et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia. 1994;37:313–20.
Rossi M, Morita H, Sormunen R, et al. Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. EMBO J. 2003;22:236–45.
van den Born J, Pisa B, Bakker MA, et al. No change in glomerular heparan sulfate structure in early human and experimental diabetic nephropathy. J Biol Chem. 2006;281:29606–13.
Nerlich A, Schleicher E. Immunohistochemical localization of extracellular matrix components in human diabetic glomerular lesions. Am J Pathol. 1991;139:889–99.
Adler SG, Feld S, Striker L, et al. Glomerular type IV collagen in patients with diabetic nephropathy with and without additional glomerular disease. Kidney Int. 2000;57:2084–92.
Truong LD, Pindur J, Barrios R, et al. Tenascin is an important component of the glomerular extracellular matrix in normal and pathologic conditions. Kidney Int. 1994;45:201–10.
Tsilibary EC. Microvascular basement membranes in diabetes mellitus. J Pathol. 2003;200:537–46.
Turbat-Herrera EA. Overview of models for the study of renal disease. In: Herrera GA, editor. Experimental models of renal diseases: pathogenesis and diagnosis, Contributions to nephrology series, vol. 169. Basel: S Karger AG; 2011. p. 1–5.
Loy A, Lurie KG, Ghosh A, Wilson JM, MacGregor LC, Matschinsky FM. Diabetes and the myo-inositol paradox. Diabetes. 1990;39:1305–12.
Alpers CE, Hudkins KL. Mouse models of diabetic nephropathy. Curr Opin Nephrol Hypertens. 2011;20:278–84.
Breyer MD, Bottinger E, Brosius III FC, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2005;16:27–45.
Chevalier J, Masurier C, Lavaud S, Michel O, Bariety J. Approach of cellular mechanisms of glomerulosclerosis in a model of accelerated aging the obese Zucker rat. C R Seances Soc Biol Fil. 1995;189:987–1007.
Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes. 2003;52:1031–5.
Regoli M, Bendayan M. Alterations in the expression of the alpha 3 beta 1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus. Diabetologia. 1997;40:15–22.
Phillips A, Janssen U, Floege J. Progression of diabetic nephropathy. Insights from cell culture studies and animal models. Kidney Blood Press Res. 1999;22:81–97.
Gassler N, Elger M, Kranzlin B, et al. Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker rat. Kidney Int. 2001;60:106–16.
Wada J, Sun L, Kanwar YS. Discovery of genes related to diabetic nephropathy in various animal models by current techniques. In: Herrera GA, editor. Experimental models of renal diseases: pathogenesis and diagnosis, Contributions to nephrology series, vol. 159. Basel: S Karger AG; 2011. p. 161–74.
Anjaneyulu M, Chopra K. Nordihydroguairetic acid, a lignin, prevents oxidative stress and the development of diabetic nephropathy in rats. Pharmacology. 2004;72:42–50.
Alpers CE, Biava CG. Idiopathic lobular glomerulonephritis (nodular mesangial sclerosis): a distinct diagnostic entity. Clin Nephrol. 1989;32:68–74.
Herzenberg AM, Holden JK, Singh S, Magil AB. Idiopathic nodular glomerulosclerosis. Am J Kidney Dis. 1999;34:560–4.
Markowitz GS, Lin J, Valeri AM, Avila C, Nasr SH, D’Agati VD. Idiopathic nodular glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking. Hum Pathol. 2002;33:826–35.
Sharma SG, Bomback AS, Radhakrishnan J, Herlitz LC, Stokes MB, Markowitz GS, D’Agati VD. The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol. 2013;8:1718–24.
Jim B, Santos J, Spath F, Cijiang He J. Biomarkers of diabetic nephropathy, the present and the future. Curr Diabetes Rev. 2012;8:317–28.
Miyata T, Suzuki N, de Strihou VY. Diabetic nephropathy: are there new and potentially promising therapies targeting oxygen biology? Kidney Int. 2013;84:693–702.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Aufman, J., Herrera, G.A. (2014). Renal Structural Changes in Type 1 and 2 Diabetes Mellitus: Pathology, Pathogenesis, and Clinical Correlations. In: Lerma, E., Batuman, V. (eds) Diabetes and Kidney Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0793-9_5
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0793-9_5
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0792-2
Online ISBN: 978-1-4939-0793-9
eBook Packages: MedicineMedicine (R0)